These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2691313)

  • 41. Serum gastrin levels during long-term omeprazole treatment.
    Koop H; Klein M; Arnold R
    Aliment Pharmacol Ther; 1990 Apr; 4(2):131-8. PubMed ID: 2104080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypergastrinemia after blockade of acid secretion in the rat: trophic effects.
    Sundler F; Håkanson R; Carlsson E; Larsson H; Mattsson H
    Digestion; 1986; 35 Suppl 1():56-69. PubMed ID: 3792672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
    Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: an indirect effect of the histamine H2-receptor antagonist, BL-6341.
    Hirth RS; Evans LD; Buroker RA; Oleson FB
    Toxicol Pathol; 1988; 16(2):273-87. PubMed ID: 2903543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats.
    Tielemans Y; Håkanson R; Sundler F; Willems G
    Gastroenterology; 1989 Mar; 96(3):723-9. PubMed ID: 2644152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach.
    Poynter D; Selway SA
    Mutat Res; 1991 Jun; 248(2):303-19. PubMed ID: 2046687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.
    Cui GL; Syversen U; Zhao CM; Chen D; Waldum HL
    Scand J Gastroenterol; 2001 Oct; 36(10):1011-5. PubMed ID: 11589371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Consequences of therapeutic long-term achlorhydria].
    Koop H; Arnold R
    Internist (Berl); 1987 Jan; 28(1):8-13. PubMed ID: 2883153
    [No Abstract]   [Full Text] [Related]  

  • 49. Review: the enterochromaffin-like cell, intragastric acidity and the trophic effect of plasma gastrin.
    Polak JM; Bloom SR
    Aliment Pharmacol Ther; 1988 Aug; 2(4):291-6. PubMed ID: 2979252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of endogenous gastrin in the development of enterochromaffin-like cell carcinoid tumors in Mastomys natalensis: a study with the specific gastrin receptor antagonist AG-041R.
    Chiba T; Kinoshita Y; Sawada M; Kishi K; Baba A; Hoshino E
    Yale J Biol Med; 1998; 71(3-4):247-55. PubMed ID: 10461356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
    Freston JW
    Ann Intern Med; 1994 Aug; 121(3):232-3. PubMed ID: 8017751
    [No Abstract]   [Full Text] [Related]  

  • 52. Gastric carcinoids of ECL cells. Pathological and clinical analysis of eight cases.
    Grigioni WF; Caletti GC; Gabrielli M; Marrano D; Villanacci V; Mancini A
    Acta Pathol Jpn; 1985 Mar; 35(2):361-75. PubMed ID: 4024941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats.
    Delwaide J; Latour P; Gast P; Louis E; Belaïche J
    Gastroenterol Clin Biol; 1993; 17(11):792-6. PubMed ID: 8143943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastric regulatory peptides in rats with reduced acid secretion.
    Bishop AE; Allen JM; Daly MJ; Larsson H; Carlsson E; Bloom SR; Polak JM
    Digestion; 1986; 35 Suppl 1():70-83. PubMed ID: 3792673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of gastric acid secretion: advantages and risks in short and long-term treatment.
    Mazzacca G; Sabbatini F
    Ital J Gastroenterol; 1990; 22 Suppl 1():11-2. PubMed ID: 1983419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study.
    Montemurro NE; Di Maggio A; Loperfido A; Franceschi M; Scatizzi A
    Clin Nephrol; 1993 Nov; 40(5):296-8. PubMed ID: 8281719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Reduction of gastric acid secretion: pathophysiologic and clinically relevant sequelae].
    Koop H; Eissele R
    Z Gastroenterol; 1991 Nov; 29(11):613-7. PubMed ID: 1685286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety profile of omeprazole. Adverse events with short-term treatment.
    Nelis GF
    Digestion; 1989; 44 Suppl 1():68-76. PubMed ID: 2691312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastric carcinoid associated with achlorhydria, hypergastrinemia, and Addison's disease.
    Bruce TA; Azmy M; Earll JM
    South Med J; 1988 Dec; 81(12):1595-6. PubMed ID: 3059527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential hazards of long-term acid suppression.
    Selway SA
    Scand J Gastroenterol Suppl; 1990; 178():85-92. PubMed ID: 1980549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.